Profile
Takao Iwayanagi is a Director for Prolexys Pharmaceuticals, Inc. and Chief Technology Officer of the Life Science Group for Hitachi Ltd.
He was appointed a Lecturer at the Tokyo Institute of Technology in 1997.
Previously, he was a Lecturer at the Universtiy of Tokyo from 1992 to 1993.
Dr. Iwayanagi received a BA degree, an MA degree in Chemistry and a PhD in Organic Chemistry from the University of Tokyo.
Former positions of Takao Iwayanagi
| Companies | Position | End |
|---|---|---|
| University of Tokyo | Corporate Officer/Principal | 01/01/1993 |
| HITACHI, LTD. | Chief Tech/Sci/R&D Officer | - |
| Tokyo Institute of Technology | Corporate Officer/Principal | - |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Director/Board Member | - |
Training of Takao Iwayanagi
| University of Tokyo | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| HITACHI, LTD. | Producer Manufacturing |
| Private companies | 1 |
|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
- Stock Market
- Insiders
- Takao Iwayanagi
